Intermittent androgen deprivation therapy with antagonist: Really new information?

摘要

Intermittent androgen deprivation (IAD) is no longer considered experimental in a selected group of patients [1]. Apart from metastasis situations, there are almost no clear indications for lifelong androgen suppression. As a salvage modality after failed local treatment, androgen suppression lacks clear evidence showing real long-term benefits [2], even if it is used frequently. Furthermore, clear evidence exists that as single modality, androgen suppression has almost no place in local or locally advanced situations [3], even though it is used in a significant cohort of patients.